Description: Regenicin, Inc. is a biotechnology company. The Company focuses on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is concentrated to be a graftable collagen based cultured epithelium implant that produces a skin substitute containing both epidermal and dermal components with a collagen base. The Company is focused on developing its product, TempaDerm. TempaDerm uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers. Regenicin Research of Georgia, LLC is the Company's subsidiary.
Home Page: www.regenicin.com
10 High Court
Little Falls,
NJ
07424
United States
Phone:
973 557 8914
Officers
| Name | Title |
|---|---|
| Mr. Randall E. McCoy | Chairman, CEO & Pres |
| Mr. John J. Weber | CFO & Director |
| Dr. J. Roy Nelson Ph.D. | Chief Science Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 3 |